Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Park PMC"'
Autor:
Li YD; Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Ma MW; Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA, USA.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Hassan MM; Department of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, CA, USA., Hunkeler M; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Teng M; Center for Drug Discovery, Department of Pathology & Immunology, and Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX, USA., Puvar K; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Rutter JC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Lumpkin RJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Sandoval B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Jin CY; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Schmoker AM; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Ficarro SB; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Blais Proteomics Center and Center for Emergent Drug Targets, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Cheong H; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Metivier RJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Wang MY; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Xu S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Byun WS; Department of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, CA, USA., Groendyke BJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., You I; Department of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, CA, USA., Sigua LH; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Tavares I; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Blais Proteomics Center and Center for Emergent Drug Targets, Dana-Farber Cancer Institute, Boston, MA, USA., Zou C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Tsai JM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Park PMC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Yoon H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Majewski FC; Department of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, CA, USA., Sperling HT; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Marto JA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Blais Proteomics Center and Center for Emergent Drug Targets, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Qi J; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Nowak RP; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Donovan KA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Słabicki M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Gray NS; Department of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, CA, USA. nsgray01@stanford.edu., Fischer ES; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. eric_fischer@dfci.harvard.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. eric_fischer@dfci.harvard.edu., Ebert BL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. benjamin_ebert@dfci.harvard.edu.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA. benjamin_ebert@dfci.harvard.edu.; Howard Hughes Medical Institute, Boston, MA, USA. benjamin_ebert@dfci.harvard.edu.
Publikováno v:
Nature chemical biology [Nat Chem Biol] 2024 Jul 29. Date of Electronic Publication: 2024 Jul 29.
Autor:
Park PMC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Park J; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Brown J; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Hunkeler M; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Roy Burman SS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Donovan KA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Yoon H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Nowak RP; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Słabicki M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Ebert BL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Howard Hughes Medical Institute, Boston, MA 02115, USA. Electronic address: benjamin_ebert@dfci.harvard.edu., Fischer ES; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA. Electronic address: eric_fischer@dfci.harvard.edu.
Publikováno v:
Molecular cell [Mol Cell] 2024 Jul 11; Vol. 84 (13), pp. 2511-2524.e8.
Autor:
Tsai JM; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Aguirre JD; Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland., Li YD; Division of Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Molecular & Cellular Biology, Harvard University, Cambridge, MA, USA., Brown J; Department of Data Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Focht V; Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland., Kater L; Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland., Kempf G; Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland., Sandoval B; Division of Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Schmitt S; Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland., Rutter JC; Division of Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Galli P; Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland; Faculty of Science, University of Basel, Basel, Switzerland., Sandate CR; Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland., Cutler JA; Pediatric Hematology-Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Zou C; Division of Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Donovan KA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Lumpkin RJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Cavadini S; Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland., Park PMC; Division of Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Sievers Q; Division of Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Hatton C; Pediatric Hematology-Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Ener E; Pediatric Hematology-Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Regalado BD; Pediatric Hematology-Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Sperling MT; Division of Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Słabicki M; Division of Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Kim J; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Zon R; Division of Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Zhang Z; Division of Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Miller PG; Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA., Belizaire R; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Sperling AS; Division of Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Fischer ES; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Irizarry R; Department of Data Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Armstrong SA; Pediatric Hematology-Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Thomä NH; Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland. Electronic address: nicolas.thoma@fmi.ch., Ebert BL; Division of Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Howard Hughes Medical Institute, Boston, MA, USA. Electronic address: benjamin_ebert@dfci.harvard.edu.
Publikováno v:
Molecular cell [Mol Cell] 2023 Aug 03; Vol. 83 (15), pp. 2753-2767.e10. Date of Electronic Publication: 2023 Jul 20.
Autor:
Zou C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Yoon H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Park PMC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Patten JJ; Department of Microbiology, Boston University School of Medicine and NEIDL, Boston University, Boston, MA 02118, USA., Pellman J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Carreiro J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Tsai JM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Li YD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Roy Burman SS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Donovan KA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Gasser J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Sperling AS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Nowak RP; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Fischer ES; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Davey RA; Department of Microbiology, Boston University School of Medicine and NEIDL, Boston University, Boston, MA 02118, USA., Ebert BL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Howard Hughes Medical Institute, Boston, MA, USA., Słabicki M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Publikováno v:
IScience [iScience] 2023 May 19; Vol. 26 (5), pp. 106601. Date of Electronic Publication: 2023 Apr 08.
Autor:
Li YD; Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA., Ma MW; Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA., Hassan MM; Department of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford , School of Medicine, Stanford University, Stanford, CA., Hunkeler M; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA., Teng M; Department of Pathology & Immunology, and Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, TX., Puvar K; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA., Lumpkin R; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA., Sandoval B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Jin CY; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA., Ficarro SB; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.; Blais Proteomics Center, and Center for Emergent Drug Targets, Dana-Farber Cancer Institute, Boston, MA., Wang MY; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA., Xu S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Groendyke BJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA., Sigua LH; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA., Tavares I; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.; Blais Proteomics Center, and Center for Emergent Drug Targets, Dana-Farber Cancer Institute, Boston, MA., Zou C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Tsai JM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA., Park PMC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA., Yoon H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA., Majewski FC; Department of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford , School of Medicine, Stanford University, Stanford, CA., Marto JA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.; Blais Proteomics Center, and Center for Emergent Drug Targets, Dana-Farber Cancer Institute, Boston, MA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA., Qi J; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA., Nowak RP; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA., Donovan KA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA., Słabicki M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA., Gray NS; Department of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford , School of Medicine, Stanford University, Stanford, CA., Fischer ES; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA., Ebert BL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Howard Hughes Medical Institute, Boston, MA.
Publikováno v:
BioRxiv : the preprint server for biology [bioRxiv] 2023 Feb 15. Date of Electronic Publication: 2023 Feb 15.
Autor:
Zaiken MC; Division of Blood & Marrow Transplant & Cellular Therapy, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Flynn R; Division of Blood & Marrow Transplant & Cellular Therapy, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Paz KG; Division of Blood & Marrow Transplant & Cellular Therapy, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Rhee SY; Division of Blood & Marrow Transplant & Cellular Therapy, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Jin S; Division of Blood & Marrow Transplant & Cellular Therapy, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Mohamed FA; Division of Blood & Marrow Transplant & Cellular Therapy, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Saha A; Division of Blood & Marrow Transplant & Cellular Therapy, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Thangavelu G; Division of Blood & Marrow Transplant & Cellular Therapy, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Park PMC; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA., Hemming ML; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA., Sage PT; Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA.; Evergrande Center for Immunologic Diseases, Harvard Medical School-Brigham and Women's Hospital, Boston, MA., Sharpe AH; Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA.; Evergrande Center for Immunologic Diseases, Harvard Medical School-Brigham and Women's Hospital, Boston, MA., DuPage M; Division of Immunology and Pathogenesis, Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, CA., Bluestone JA; University of California San Francisco, San Francisco, CA., Panoskaltsis-Mortari A; Division of Blood & Marrow Transplant & Cellular Therapy, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Cutler CS; Division of Hematologic Malignancies., Koreth J; Division of Hematologic Malignancies., Antin JH; Division of Hematologic Malignancies., Soiffer RJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Ritz J; Division of Hematologic Malignancies., Luznik L; Department of Oncology, Sidney Kimmel Cancer Center, Baltimore, MD., Maillard I; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA., Hill GR; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Division of Medical Oncology, University of Washington, Seattle, WA., MacDonald KPA; Department of Immunology, Queensland Institute of Medical Research (QIMR), University of Queensland, Brisbane, QLD, Australia., Munn DH; Georgia Cancer Center, Augusta University, Augusta, GA., Serody JS; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC., Murphy WJ; Department of Dermatology, School of Medicine, University of California, Davis, Sacramento, CA., Kean LS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.; Boston Children's Hospital, Dana-Farber Cancer Institute, Boston, MA., Zhang Y; Fels Institute for Cancer Research and Molecular Biology, Department of Microbiology and Immunology, Temple University, Philadelphia, PA., Bradner JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and., Qi J; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Blazar BR; Division of Blood & Marrow Transplant & Cellular Therapy, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN.
Publikováno v:
Blood [Blood] 2022 May 12; Vol. 139 (19), pp. 2983-2997.
Autor:
Durbin AD; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.; The Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Division of Molecular Oncology, Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee., Wang T; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Wimalasena VK; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Zimmerman MW; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Li D; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Dharia NV; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.; The Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Mariani L; Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Shendy NAM; Division of Molecular Oncology, Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee., Nance S; Division of Molecular Oncology, Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee., Patel AG; Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee., Shao Y; Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee., Mundada M; Division of Molecular Oncology, Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee., Maxham L; Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee., Park PMC; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Sigua LH; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Morita K; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Conway AS; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Robichaud AL; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Perez-Atayde AR; Department of Pathology, Boston Children's Hospital, Boston, Massachusetts., Bikowitz MJ; Drug Discovery Department, Moffit Cancer Center, Tampa, Florida.; Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida., Quinn TR; Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana., Wiest O; Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana., Easton J; Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee., Schönbrunn E; Drug Discovery Department, Moffit Cancer Center, Tampa, Florida.; Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida., Bulyk ML; The Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Abraham BJ; Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee., Stegmaier K; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.; The Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Look AT; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts., Qi J; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts.
Publikováno v:
Cancer discovery [Cancer Discov] 2022 Mar 01; Vol. 12 (3), pp. 730-751.
Autor:
Ohguchi H; Division of Disease Epigenetics, Institute of Resource Development and Analysis, Kumamoto University, Kumamoto, Japan. ohguchi@kumamoto-u.ac.jp Kenneth_anderson@dfci.harvard.edu teru_hideshima@dfci.harvard.edu jun_qi@dfci.harvard.edu., Park PMC; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Wang T; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Gryder BE; Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.; Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Case Comprehensive Cancer Center, Cleveland, Ohio., Ogiya D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Kurata K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Zhang X; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Li D; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Pei C; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Masuda T; Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan., Johansson C; Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom., Wimalasena VK; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Kim Y; Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Hino S; Department of Medical Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto, Japan., Usuki S; Liaison Laboratory Research Promotion Center, Institute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto, Japan., Kawano Y; Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University School of Medicine, Kumamoto, Japan., Samur MK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Tai YT; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Munshi NC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Matsuoka M; Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University School of Medicine, Kumamoto, Japan., Ohtsuki S; Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan., Nakao M; Department of Medical Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto, Japan., Minami T; Division of Molecular and Vascular Biology, Institute of Resource Development and Analysis, Kumamoto University, Kumamoto, Japan., Lauberth S; Division of Biological Sciences, University of Califonia, San Diego, La Jolla, California., Khan J; Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Oppermann U; Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.; Structural Genomics Consortium, University of Oxford, Headington, United Kingdom; Oxford Centre for Translational Myeloma Research, Botnar Research Centre, University of Oxford, Oxford, United Kingdom., Durbin AD; Division of Molecular Oncology, Department of Oncology, and Comprehensive Cancer Center, St. Jude Children's Research Hospital, Memphis, Tennessee., Anderson KC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. ohguchi@kumamoto-u.ac.jp Kenneth_anderson@dfci.harvard.edu teru_hideshima@dfci.harvard.edu jun_qi@dfci.harvard.edu.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Hideshima T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. ohguchi@kumamoto-u.ac.jp Kenneth_anderson@dfci.harvard.edu teru_hideshima@dfci.harvard.edu jun_qi@dfci.harvard.edu., Qi J; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. ohguchi@kumamoto-u.ac.jp Kenneth_anderson@dfci.harvard.edu teru_hideshima@dfci.harvard.edu jun_qi@dfci.harvard.edu.; Department of Medicine, Harvard Medical School, Boston, Massachusetts.
Publikováno v:
Blood cancer discovery [Blood Cancer Discov] 2021 Jul; Vol. 2 (4), pp. 370-387. Date of Electronic Publication: 2021 Apr 10.
Autor:
Song Y; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Park PMC; Department of Cancer Biology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA, USA., Wu L; Department of Cancer Biology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA, USA., Ray A; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Picaud S; University of Oxford, Oxford, UK., Li D; Department of Cancer Biology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA, USA., Wimalasena VK; Department of Cancer Biology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA, USA., Du T; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Filippakopoulos P; University of Oxford, Oxford, UK., Anderson KC; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Kenneth_Anderson@dfci.harvard.edu., Qi J; Department of Cancer Biology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA, USA. Jun_Qi@dfci.harvard.edu., Chauhan D; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Dharminder_Chauhan@dfci.harvard.edu.
Publikováno v:
Leukemia [Leukemia] 2019 Nov; Vol. 33 (11), pp. 2685-2694. Date of Electronic Publication: 2019 Apr 08.
Autor:
Pak E; Departments of Cancer Biology and Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Neurobiology, Harvard Medical School, Boston, Massachusetts, USA., MacKenzie EL; Departments of Cancer Biology and Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Neurobiology, Harvard Medical School, Boston, Massachusetts, USA., Zhao X; Departments of Cancer Biology and Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Neurobiology, Harvard Medical School, Boston, Massachusetts, USA., Pazyra-Murphy MF; Departments of Cancer Biology and Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Neurobiology, Harvard Medical School, Boston, Massachusetts, USA., Park PMC; Department of Cancer Biology and Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA., Wu L; Department of Cancer Biology and Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA., Shaw DL; Department of Cancer Biology and Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA., Addleson EC; Departments of Cancer Biology and Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Neurobiology, Harvard Medical School, Boston, Massachusetts, USA., Cayer SS; Departments of Cancer Biology and Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Neurobiology, Harvard Medical School, Boston, Massachusetts, USA., Lopez BG; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Agar NYR; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Rubin LL; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts, USA.; Harvard Stem Cell Institute, Cambridge, Massachusetts, USA., Qi J; Departments of Cancer Biology and Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Cancer Biology and Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA., Merk DJ; Departments of Cancer Biology and Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Neurobiology, Harvard Medical School, Boston, Massachusetts, USA.; Hertie-Institute for Clinical Brain Research, Eberhard Karls University, Tübingen, Germany., Segal RA; Departments of Cancer Biology and Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Neurobiology, Harvard Medical School, Boston, Massachusetts, USA.
Publikováno v:
Neuro-oncology [Neuro Oncol] 2019 Sep 06; Vol. 21 (9), pp. 1150-1163.